Abstract
Down’s Syndrome (DS) is associated with premature and accelerated ageing and a propensity for early-onset Alzheimer’s disease (AD). The early symptoms of dementia in people with DS may reflect frontal lobe vulnerability to amyloid deposition. The Mismatch Negativity (MMN) is a frontocentral component elicited by auditory violations of expected sensory input and it reflects sensory memory and automatic attention switching. In the typically developing (TD) population, the MMN response has been found to decrease with age. In the cross-sectional phase of this study the MMN was used to investigate the premature neurological ageing hypothesis of DS. In the longitudinal phase, we evaluated the MMN as a potential predictor of cognitive decline. The study found that age predicted MMN amplitude in DS but not in those who are TD, showing that the MMN reflects accelerated ageing in DS. However, a follow-up of 34 adults with DS found that neither amplitude nor latency of the MMN predicted cognitive decline one year later.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Medical Research Council, The Health Foundation, Addenbrooke's Charitable Trust, Alzheimer's Research UK Pump Priming Grant - Cambridge Network, Fearnsides Fund, and Marmaduke Sheild Fund funded this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval to conduct the study (reference 14/LO/1411) was given by the National Research Ethics Service (NRES). The Committee had the expertise to assess studies that might include individuals who lacked capacity to consent to participation in research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, CA, upon reasonable request.
